The Journal of Sexual Medicine · 2016 · 21 citations · 13 references
MedicineEndocrinologyUrologyAndrologyMen's HealthReproductive EndocrinologyErectile DysfunctionHormonal EvaluationMale Reproductive EndocrinologyMale SexualitySexual DysfunctionTesticular FunctionEjaculatory Function AssessmentHormonal Influences On EjaculationHypothalamic-pituitary-gonadal Axis DysfunctionLibido Evaluation In MalesMale Sexual DysfunctionMale Sexual FunctionPharmacotherapy For Ejaculatory DisordersTestosterone Therapy
INTRODUCTION: Hypogonadism is defined as decreased testosterone levels in men. Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction. AIMS: To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men. METHODS: Sexually active, hypogonadal men at least 18 years old (total testosterone < 300 ng/dL) were randomized to receive testosterone or placebo for 12 weeks. MAIN OUTCOME MEASURES: Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Men's Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form (MSHQ-EjD-SF) questionnaires. Treatment differences were calculated using analysis of covariance. RESULTS: In total, 715 men (mean age = 55 years) were randomized to placebo (n = 357) or testosterone (n = 358). Most sexually active men who reported IIEF scores had some degree of erectile dysfunction (IIEF erectile function score < 26). Although ejaculatory function score (MSHQ-EjD-SF) improved in the testosterone group compared with placebo (P < .001), improvement on the "bother" item did not reach statistical significance. Treatment-related adverse events in the testosterone group affecting at least 1% of patients were increased hematocrit, upper respiratory tract infection, arthralgia, burning sensation, fatigue, increased prostate-specific antigen, erythema, and cough. Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475). CONCLUSION: Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.
13
Edward O. Laumann, A. Nicolosi, Dale B. Glasser et al. · International Journal of Impotence Research · 2004 · 1.4K citations · Full text
Steven M. Petak, Howard R. Nankin, Richard F. Spark et al. · Endocrine Practice · 2002 · 372 citations